EMVision Medical Devices (ASX:EMV) started a validation trial for its first commercial device, the emu bedside brain scanner, to support a De Novo clearance from the US Food and Drug Administration, a filing on the Australian bourse on Thursday showed.
The company secured an Australian ethics approval, and The Royal Melbourne Hospital was greenlit as the first Australian hospital after a successful site initiation visit. Operator training is in progress.
An emu device was shipped to the first US site, the University of Texas Health Science Center at Houston Medical School and Memorial Hermann-Texas Medical Center. A site initiation visit is planned for the coming weeks.
Further trial sites in the US and Australia will be named and activated shortly, per the filing.
The scanner is a non-invasive, non-ionizing device that uses ultra-high frequency radiofrequency scanning technology combined with advanced artificial intelligence-based algorithms to assist in point-of-care stroke diagnosis.
The company's shares gained over 5% in recent trading on Thursday.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。